NLRP3 and metabolic disease: Notably, we reported for the first time that IL-22 gene therapy not only suppressed the systemic pathogenesis of DN, including hyperglycemia and metabolic disorders, but also protected against renal pathogenesis via suppression of NLRP3 inflammasome activation.